The prognostic value of time from symptom onset to thrombolysis in patients with pulmonary embolism
Yükleniyor...
Dosyalar
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Ireland Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background: According to clinical practice guidelines, thrombolysis can be administered during the 14 days after the beginning of symptoms in PE. However, the role of the early thrombolysis in PE has not been comprehensively investigated. In this study we evaluated the effect of short symptom-to-thrombolysis time (STT) in these patients who received the thrombolytic therapy within the 48-h. Method: A total of 456 patients with pulmonary embolism who underwent thrombolytic therapy in a tertiary center were included in the current study. The patients were stratified into three groups according to STT as: <12 h (Group 1), 12 to 24 h (Group 2) and > 24 to 48 h (Group 3). In-hospital events and long-term mortality were compared between the groups. Results: Group 3 had higher in-hospital mortality, acute kidney injury, cardiogenic shock, asystole, and the use mechanical ventilation and 3-year mortality compared to the other two groups. The 3-year overall survival for Group 1, 2 and 3 were 82.1%, 77.7% and 25.9% respectively. According to regression analysis, a STT > 24 h was independently associated with in-hospital and long-term mortality. Group 1 and 2 had similar in-hospital outcomes and long-term mortality. Conclusion: A short STT has a great importance in patients with PE who treated with thrombolytic therapy. The efficacy of systemic thrombolysis significantly drops after 24 h. Because of this situation, the period between the symptom onset and thrombolytic therapy should be kept short as much as possible. © 2022
Açıklama
Anahtar Kelimeler
Pulmonary embolism, Thrombolysis, tissue plasminogen activator, fibrinolytic agent, acute kidney failure, aged, all cause mortality, Article, artificial ventilation, bleeding, brain hemorrhage, cardiogenic shock, controlled study, female, fibrinolytic therapy, heart arrest, human, in-hospital mortality, long term mortality, lung embolism, major clinical study, male, mortality, mortality rate, overall survival, prognosis, proportional hazards model, retrospective study, survival rate, symptom to thrombolysis time, tertiary care center, time, adverse event, lung embolism, prognosis, treatment outcome, Fibrinolytic Agents, Humans, Prognosis, Pulmonary Embolism, Thrombolytic Therapy, Treatment Outcome
Kaynak
International Journal of Cardiology
WoS Q Değeri
Q2
Scopus Q Değeri
N/A
Cilt
352
